Year: 2017
Language: English
This resource is also available in: Spanish
Author(s): Albert Farrugia
The purpose of this guide is to inform and facilitate the selection and purchase of therapeutic products for the treatment of hemophilia.
It discusses the factors that contribute to the quality, safety, and efficacy of hemophilia treatment products and, in particular, the provisions made for ensuring that these products are free of viruses. It covers well-established systems in the United States and the European Union that regulate and control therapeutic products for hemophilia.
For regulatory agencies in countries without established systems, this guide provides guidance for the development of procedures, and offers a model for the evaluation of products, to ensure the safety and quality of therapeutic products for hemophilia.
The WFH Shared Decision Making (SDM) Tool is an interactive decision-support system designed to facilitate discussions regarding treatment options between
This fact sheet contains commonly asked questions and more information on gene therapy for hemophilia B. Learn more about different
This video gives a quick introduction to gene therapy for hemophilia. Learn more about different treatment options for hemophilia with
This video gives a quick introduction to hemostatic rebalancing therapy. Learn more about different treatment options for hemophilia with the
This fact sheet contains commonly asked questions and more information on gene therapy for hemophilia A. Learn more about different
This fact sheet contains commonly asked questions and more information on hemostatic rebalancing therapy. Learn more about different treatment options
